Loading
A phase 1/2 trial of BMS-986369 in peripheral T-cell lymphomas, run by Bristol-Myers Squibb, active and no longer recruiting.
A Study to Assess the Safety, Tolerability, Efficacy, and Drug Levels of BMS-986369 (Golcadomide) in Participants With Relapsed or Refractory T-cell Lymphomas in Japan (GOLSEEK-3) is a phase 1/2 interventional study registered as NCT06035497 by Bristol-Myers Squibb, with 85 participants enrolled, started 2023-11-20 and due to reach its primary completion in 2027-01-30. Interventions recorded: BMS-986369.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Bristol Myers Squibb and the tag pipeline.
Shares Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma) and the tag pipeline.
Shares Bristol Myers Squibb and the tag pipeline.
Shares Bristol Myers Squibb and the tag pipeline.
Shares Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma) and the tag pipeline.
Shares Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma) and the tag pipeline.
Shares Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma) and the tag pipeline.
Shares Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/